Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma

A study for patients diagnosed with advanced cutaneous T-cell lymphoma (stage 1B or higher) who have progressive, persistent, or recurrent disease on or following 2 other therapies, one of which must have contained Targretin (bexarotene)or for patients who are not candidates or could not tolerate Targretin therapy.

Inclusion Criteria:

• Patients with Cutaneous T-cell Lymphoma (Stage 1B or higher)
• Age: over 18 years of age
• Have the ability to swallow capsules.
• You must be at least 3 weeks from any prior chemotherapy or anticancer therapy treatment and have recovered from any side effects of that treatment.
• Patients also require adequate heart, liver, and kidney function.

Exclusion Criteria:

• Pregnant and nursing women and those with known allergy to the study drug are excluded from this study.
• Patients are excluded if they are currently receiving chemotherapy, radiation therapy, or other investigational anti-cancer therapy.
• Patients diagnosed with HIV, active hepatitis or who require intravenous antibiotics or antifungal agents are not permitted.